Brokerages Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70

UroGen Pharma Ltd. (NASDAQ:URGN) has earned an average rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $43.70.

URGN has been the subject of a number of analyst reports. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. Oppenheimer reissued an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Friday. Finally, Guggenheim began coverage on UroGen Pharma in a research note on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective for the company.

UroGen Pharma Stock Performance

URGN opened at $12.29 on Friday. UroGen Pharma has a 12-month low of $10.60 and a 12-month high of $20.70. The firm has a market capitalization of $288.25 million, a P/E ratio of -3.90 and a beta of 1.06. The stock’s 50 day moving average price is $12.28 and its two-hundred day moving average price is $13.97. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the previous year, the company earned ($0.68) earnings per share. On average, equities analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. RTW Investments LP increased its holdings in UroGen Pharma by 6.5% in the third quarter. RTW Investments LP now owns 3,787,347 shares of the company’s stock valued at $48,099,000 after purchasing an additional 230,000 shares during the last quarter. Great Point Partners LLC increased its stake in shares of UroGen Pharma by 10.9% in the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock valued at $48,767,000 after acquiring an additional 285,714 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after acquiring an additional 1,337,257 shares during the last quarter. Cowen AND Company LLC raised its position in shares of UroGen Pharma by 29.1% in the 2nd quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock valued at $35,229,000 after acquiring an additional 472,893 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in UroGen Pharma by 1.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company’s stock worth $17,032,000 after acquiring an additional 21,072 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.